Tarextuma OMP 59R5 represents a significant clinical modality targeting NOTCH2 , a key molecule implicated in various hematologic diseases. This human antibody selectively binds to Notch-2 , inhibiting its activation and demonstrating early promise in numerous settings of T-cell malignancies . T

Demcizumab, also known as OMP 21M18 and bearing the CAS registry number 1243262-17-0, constitutes a promising monoclonal immunoglobulin targeting selectively blocking certain function of angiopoietin- TIE 2. Research demonstrate this compound has the promise for addressing multiple ophthalmic con

Recombinant murine granulocyte colony-stimulating protein, often abbreviated as G-CSF, represents a significant therapeutic molecule in modern clinical practice. Produced via modern molecular techniques, this protein is essentially a refined version of a endogenously occurring growth factor that